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Objective: The impact of any intervention on renal function is a crucial determinant of outcome. Open (OR) and
endovascular (EVAR) abdominal aortic aneurysm (AAA) repair can affect renal function during the short and longer
term. This study aimed to directly compare the effect of those different types of aneurysm repair during a period of
2 years.
Methods: This was a nested case-control study including patients undergoing either OR or EVAR of an infrarenal AAA.
Three groups were included: OR, EVAR with suprarenal endograft ﬁxation, and EVAR with infrarenal ﬁxation. These
were matched for age (within 2 years), sex, AAA size (within 1 cm), hypertension, smoking, and proximal neck diameter
(within 5 mm). The primary end point was change in estimated glomerular ﬁltration rate (eGFR) calculated by the
Chronic Kidney Disease Epidemiology Collaboration formula at baseline, 6 months, 12 months, and 2 years.
Results: A total of 225 patients were included [(45 ORs matched vs 90 suprarenal and 90 infrarenal ﬁxation EVARs; 35
women (16%); age, 71 6 8 years; AAA size, 6.4 6 1 cm]. Groups did not differ signiﬁcantly in terms of diabetes,
hypercholesterolemia, or baseline eGFR (P[ .89). On average, those undergoing OR lost a mean 5.39 mL/min/1.73 m2
(P[ .48) within 1 year and 5.49 units (P[ .42) after 2 years. The suprarenal ﬁxation patients lost 5.58 units (P[ .002)
after 1 year and 6.57 units (P[ .001) after 2 years. Finally, the infrarenal ﬁxation patients lost 0.53 unit (P[ .74) after
1 year and 2.24 units (P [ .22) after 2 years.
Conclusions: OR and suprarenal ﬁxation EVAR are associated with signiﬁcant declines in renal function during 2 years, in
contrast to infrarenal EVAR ﬁxation. The patterns of eGFR decline in OR and suprarenal ﬁxation EVAR are not similar,
suggesting different causal mechanisms. (J Vasc Surg 2014;60:597-603.)Abdominal aortic aneurysm (AAA) can be present in
up to 5% of men older than 65 years in certain populations,
representing a signiﬁcant health problem.1 Endovascular
aneurysm repair (EVAR) is now routinely performed in pa-
tients with favorable anatomy, as early and medium-term
morbidity and mortality have proved similar or even supe-
rior to open repair (OR).2-4 Both OR (through manipula-
tions of the abdominal aorta possibly leading to renal artery
trauma, prolonged operating time, cross-clamping, and
need for general anesthesia) and EVAR (through endolu-
minal manipulations, intra-arterial administration of
contrast material during the procedure, microemboliza-
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://dx.doi.org/10.1016/j.jvs.2014.03.282may adversely affect renal function in the short and longer
term. Various attempts have been made to investigate this.
However, studies that aimed to delineate the impact of
open AAA repair in comparison to EVAR on renal function
have provided inconclusive and conﬂicting results. Such
previous attempts suffered from important limitations,
like the use of suboptimal measures of renal dysfunction,5
short duration of follow-up,6 retrospective design,7,8
absence of differentiation between suprarenal and infrare-
nal ﬁxation during EVAR,7,8 and lack of appropriate
matching resulting in imbalanced groups.5-10
In studies that showed EVAR to be associated with
worse renal function than open AAA repair, it was sug-
gested that the use of contrast material during the proce-
dure and follow-up radiologic investigations was a causal
factor5,7; however, it is unknown whether the related
studies have included standardized protocols for renal pro-
tection during the procedure or standardized patterns of
radiologic follow-up. In addition, several studies have
grouped together patients undergoing suprarenal and
infrarenal EVAR ﬁxation7,8 or included patients with supra-
renal ﬁxation only9; however we have recently shown in a
direct comparison that only suprarenal ﬁxation adversely
affects renal function during the course of 1 year,11 and
thus differentiation between the two groups is necessary
for any conclusions to be made. Further, serum creatinine
concentration has long been known to be an imprecise597
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developed to provide more accurate estimates of renal
function, the Cockcroft and Gault13 equation carries
some limitations, whereas the Modiﬁcation of Diet in
Renal Disease (MDRD) study equation14 provides an ac-
curate estimate of glomerular ﬁltration rate (GFR), and
the recently developed Chronic Kidney Disease Epidemi-
ology Collaboration (CKD-EPI) equation has been pro-
posed as a better alternative to the MDRD formula.15,16
The aim of this study was to evaluate, with a controlled
design, the effects of open AAA repair in comparison to
both suprarenal and infrarenal EVAR procedures at
6, 12, and 24 months on renal function changes measured
with the use of estimated GFR (eGFR) derived from the
most contemporary formula (CKD-EPI equation).
METHODS
Study design and population
This is a nested case-control analysis including patients
undergoing elective OR or EVAR of an infrarenal AAA be-
tween January 2008 and May 2011 in two tertiary referral
centers. Patients were eligible for EVAR or OR if they had
an AAA diameter >5.5 cm or an AAA diameter <5.5 cm
with a rapidly increasing sac (>1 cm per year). EVAR
was offered as a ﬁrst-line procedure after discussion at a
multidisciplinary meeting, unless the patient opted for
OR after consultation; none of the patients in this series
had a pararenal or suprarenal AAA or excessive thrombus
at the level of the proximal aneurysmal neck. Indications
for the deployment of a stent graft with suprarenal ﬁxation
were an infrarenal aneurysmal neck <14 mm in length or a
proximal aneurysmal neck of conical shape.17
Patients were included in the analysis if they completed
at least 2 years of follow-up and had all relevant informa-
tion available. Patients with symptomatic, leaking,
ruptured, infected, or inﬂammatory aneurysms and patients
with end-stage renal disease receiving renal replacement
therapy at baseline were excluded. The original cohort con-
sisted of 389 patients who underwent EVAR and 48 pa-
tients who underwent OR. Those undergoing EVAR
were divided in two groups according to the mode of
proximal aortic ﬁxation of the endograft in relation to the
oriﬁce of the renal arteries (suprarenal or infrarenal ﬁxation
mechanism). A total of 139 patients had undergone EVAR
with a device bearing suprarenal ﬁxation, and 250 patients
had undergone EVAR with a device without. To form the
ﬁnal study groups, two investigators blinded to patient data
apart from age, sex, AAA diameter, ﬁxation type, and
smoking habit matched patients from the OR group (cases)
with individuals from the two EVAR ﬁxation groups for
age (within 2 years), sex, AAA diameter (within 1 cm),
length of the proximal aneurysmal neck (within 5 mm),
presence of hypertension, and smoking habit (never, cur-
rent smoker, ex-smoker). A total of 45 patients undergoing
OR were matched to patients undergoing suprarenal or
infrarenal ﬁxation EVAR in a 1:2:2 ratio. This represented
the ﬁnal population of the analysis.Study protocol
Baseline demographics and comorbidities were recorded
and stored electronically. All participants underwent computed
tomography angiography (CTA) with reconstruction. Blood
samples were obtained before any imaging requiring the
administration of contrast material at baseline and at all study
intervals. A standard follow-up protocol, including laboratory
checks at 30 days, 6 months, and 12 months after the opera-
tion and annually thereafter, was used in all patients. For
EVAR patients, imaging at these intervals included plain
abdominal radiography and CTA at 6 months, 12 months,
and annually thereafter. For those undergoing OR, no
cross-sectional imaging was obtained routinely during
follow-up. Written informed consent was obtained.
Procedures
EVAR. The following devices were used: Anaconda
(Vascutek, Scotland, UK), Gore Excluder (Gore, Flagstaff,
Ariz), Endurant and Talent (Medtronic, Minneapolis,
Minn), and EndoFit (LeMaitre, Burlington, Mass). Indica-
tions and speciﬁcations have been described elsewhere.18-21
All procedures were performed in an operating theater un-
der general anesthesia. Iopromide was used as contrast me-
dium(Ultravist 300;Bayer,Berlin,Germany). For all EVARs,
1.2 g of oral N-acetylcysteine was administered 24 hours
beforeEVAR.The administrationof any contrastmedium for
at least 2 weeks and nonsteroidal anti-inﬂammatory drugs for
at least 1 week before EVAR was avoided. Metformin was
discontinued 2 days before EVAR. For patients with a pre-
operative eGFR >60 mL/min/1.73 m2, intravenous ﬂuids
(0.9% saline, 2 mL/kg/h) were started on the day of the
operation. Patients with an eGFR <60 units were admitted
1 day before and received intravenous ﬂuids (0.9% saline,
1.5 L/24 h) for 24 hours, until nil bymouth, when theywere
commenced on 0.9% saline at 2 mL/kg/h. Urinary cathe-
terization and hourly urine output measurements were
routinely employed. In accordance with our standard pro-
tocol for elective EVAR, aspirin and clopidogrel were
administered the day of the procedure. Aspirin was dis-
continued on day 30, and clopidogrel was continued as a
lifelong treatment.22 The patient was ambulated as soon as
possible and usually discharged on day 2.
OR. All procedures were performed in an operating
theater under general anesthesia. A Dacron or polytetra-
ﬂuoroethylene graft was anastomosed in standard fashion.
None of the patients required suprarenal clamping. Stan-
dard cardiac monitoring was available, including cardiac
output measurement and central line monitoring. Speciﬁc
renoprotective modalities, such as preoperative intravenous
hydration or bicarbonate infusion, were not used. Patients
remained in an intensive care unit for at least 24 hours.
Urinary catheterization and hourly urine output measure-
ments were routinely employed during and after the
procedure. All patients were already taking aspirin preoper-
atively, which was continued as a lifelong treatment.
The patient was ambulated and discharged as soon as
possible.
Table I. Characteristics of interest for the study groups at baseline
OR (n ¼ 45)
EVAR
PSuprarenal ﬁxation (n ¼ 90) Infrarenal ﬁxation (n ¼ 90)
Age, years, mean 6 SD 71 6 9 71 6 8 71 6 8 .9
Female sex 7 14 14 1
AAA size, mean 6 SD 6.7 6 1.2 6.4 6 1.2 6.2 6 1.1 .08
Smoking 19 38 38 1
Hypertension 39 78 78 1
Diabetes 4 9 7 .9
Hypercholesterolemia 27 50 56 .8
Statin use 31 70 64 .5
CVD 6 12 16 .7
PAD 9 14 8 .2
Stroke or TIA 2 10 2 .04
Proximal neck length,a mm 14 (4) 15 (3) 19 (4) .001
Proximal neck diametera 24 (3) 24 (12) 22 (3) .01
Serum creatinine, mg/dL 1.1 6 .3 1.1 6 .3 0.9 6 0.3 .3
eGFR, mL/min/1.73 m2 76 6 29 76 6 27 75 6 23 .9
AAA, Abdominal aortic aneurysm; CVD, cardiovascular disease; eGFR, estimated glomerular ﬁltration rate (by the Chronic Kidney Disease Epidemiology
Collaboration formula); EVAR, endovascular aneurysm repair; OR, open repair; PAD, peripheral arterial disease; SD, standard deviation; TIA, transient
ischemic attack.
aData presented as median (interquartile range).
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The primary end point of this study was change in renal
function assessed with eGFR, which was calculated from
standardized serum creatinine measurements by use of
the CKD-EPI equation.15 Of note, all subjects were white.
All postoperative events, including endoleak and device-
related complications, were deﬁned and classiﬁed according
to the reporting standards by Chaikof et al23
Statistical analysis
Analyses were performed with the Statistical Package
for Social Sciences version 21.0 (SPSS, Chicago, Ill).
Continuous parametric data are presented as mean
value 6 standard deviation, and categorical data are pre-
sented as absolute values and percentages. Nonparametric
data are presented as median and interquartile range. Com-
parisons between the study groups were performed with
analysis of variance testing for continuous parametric vari-
ables and Pearson c2 test for categorical variables. The
Kruskal-Wallis test was used to test differences between
nonparametric variables. Differences between the baseline
and the various study intervals within each study group
were assessed by paired samples t-tests. Pearson correlation
was used to assess the correlation between baseline prox-
imal neck length and drop in eGFR. A P value <.05 was
considered statistically signiﬁcant.
RESULTS
Baseline characteristics and procedures. A total of
225 patients were included (45 ORs matched against 90
suprarenal and 90 infrarenal ﬁxation EVARs; 35 women
[16%]; age, 71 6 8 years; AAA size, 6.4 6 1 cm).
Table I summarizes baseline characteristics. Apart fromage, sex, hypertension, and smoking habit, for which the
three groups were matched at baseline as detailed before,
patients did not differ in terms of diabetes (P ¼ .9), hy-
percholesterolemia (P ¼ .8), and use of statins (P ¼ .5).
None of the patients had a juxtarenal aneurysm, none
required suprarenal clamping, and none had more than
50% of calciﬁcation or thrombus at the proximal neck.
Baseline serum creatinine concentration and eGFR did not
differ (P ¼ .9; Table I). None of the EVAR patients had a
severely angulated proximal neck (>45). Infrarenal sup-
port devices deployed included Anaconda bifurcated device
(84 patients) and Gore Excluder bifurcated device
(six patients). Devices with suprarenal support included
Endurant bifurcated device (64 patients), EndoFit tubular
aortic graft (18 patients), and Talent bifurcated device
(eight patients).
None of the patients died during the procedure, and
none of the EVARs were converted to open. The amount
of contrast medium used during deployment (120 6 28 vs
124 6 21 mL; P ¼ .9) was not signiﬁcantly different
between the two EVAR groups. None of the main renal
arteries were covered. Overall, four accessory renal arteries
were covered in the suprarenal and three in the infrarenal
EVAR ﬁxation groups; none of the OR patients had an
accessory renal artery. No further renal sequelae were
observed intraoperatively.
Procedure-related events during follow-up. All
patients completed at least 2 years of follow-up (mean
follow-up, 44 6 13 months). During that time, a total of
13 (6%) deaths occurred (Table II). None of the patients
developed renal infarcts, renal artery occlusion, or dissec-
tion on the basis of CTA. A total of 11 (12%) and six (6%)
type II endoleaks occurred in the suprarenal and infrarenal
groups, respectively (P ¼ .04); all patients remained under
Table II. Events during follow-up
OR
EVAR
P
Suprarenal
ﬁxation
Infrarenal
ﬁxation
Death 5 2 6 .1
Myocardial infarction 3 9 7 .1
Stroke 4 5 7 .9
Critical limb ischemia 3 6 7 1
Postoperative hypotension
requiring inotropic
support
9 2 1 .32
Endoleak type I d 5 4 1
Endoleak type II d 11 6 .04
Number of CTAs
during 2 yearsa
1 (0-3) 4 (4-7) 4 (3-7) .001
CTA, Computed tomography angiography; EVAR, endovascular aneurysm
repair; OR, open repair.
aData presented as median and range.
Table III. Renal outcomes
Time 0 months 6 months 12 months 24 months
SCr
OR 1.1 6 0.3 1.1 6 0.3 1.1 6 0.3 1.1 6 0.4
EVAR
SR 1.1 6 0.3 1.0 6 0.4 1.1 6 0.4 1.1 6 0.4
IR 1.0 6 0.3 1.1 6 0.3 1.0 6 0.3 1.0 6 0.4
eGFR
OR 76 6 29 72 6 29 71 6 26 73 6 25
EVAR
SR 76 6 28 75 6 29 71 6 28 71 6 27
IR 75 6 23 77 6 26 74 6 24 74 6 24
eGFR, Estimated glomerular ﬁltration rate (by the Chronic Kidney Disease
Epidemiology Collaboration formula in mL/min/1.73 m2); EVAR,
endovascular aneurysm repair; IR, infrarenal ﬁxation; OR, open repair; SCr,
serum creatinine concentration (mg/dL); SR, suprarenal ﬁxation.
Table IV. Changes in eGFR during the 2-year study
period
Group Time interval
Mean drop
of eGFR SE of mean P
OR Baselinee6 months 4.4 3.0 .15
6-12 months 1.0 1.8 .57
12-24 months 0.1 1.5 .94
Baselinee12 months 5.4 2.7 .06
Baselinee24 months 5.5 2.6 .04
EVAR SR Baselinee6 months 0.9 2.0 .66
6-12 months 4.7 1.4 .001
12-24 months 1.1 .9 .25
Baselinee12 months 5.5 1.8 .01
Baselinee24 months 6.6 2.0 .001
EVAR IR Baselinee6 months 2.2 1.8 .23
6-12 months 2.7 1.2 .03
12-24 months 2.1 .8 .01
Baselinee12 months 0.5 1.6 .74
Baselinee24 months 2.2 1.8 .22
eGFR, Estimated glomerular ﬁltration rate (by the Chronic Kidney Disease
Epidemiology Collaboration formula in mL/min/1.73 m2); EVAR,
endovascular aneurysm repair; IR, infrarenal ﬁxation; OR, open repair; SE,
standard error; SR, suprarenal ﬁxation.
Fig. Changes in estimated glomerular ﬁltration rate (eGFR) at 6,
12, and 24 months of follow-up in the open repair (OR) and su-
prarenal and infrarenal endovascular aneurysm repair (EVAR)
procedures. P values for comparisons between baseline and
24 months in each group.
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did not undergo any additional imaging that would have
required the administration of contrast material. A total of
ﬁve (6%) and four (6%) type I endoleaks occurred in the
suprarenal and infrarenal groups, respectively (P ¼ 1); seven
of these were identiﬁed intraoperatively, and two (both in
the infrarenal group) occurred and were treated within
2 months of the repair. They were managed successfully
with the deployment of an endovascular cuff. None of the
OR patients required reintervention during the 2-year
period. No renal infarcts were noted on the follow-up
CTAs. Overall, seven patients in the suprarenal group,
eight patients in the infrarenal group, and three patients in
the OR group underwent an endovascular procedure
necessitating administration of contrast material (angiog-
raphy of the lower limbs in nine cases, angioplasty of the
lower limbs in seven cases, and cuff deployment for endoleak
in two cases as described before) during the 2-year period.
Renal outcomes. None of the patients progressed to
end-stage renal disease and none required hemodialysis
during the 2 years. Further, none of the patients presenteda drop of eGFR that exceeded 30%. Table III summarizes
measures of renal function during follow-up. When within-
group comparisons were performed (Table IV; Fig), in the
open group, eGFR dropped from 76 6 29 mL/min/
1.73 m2 to 72 6 29 (P ¼ .15) at 6 months, 71 6 26 (P ¼
.05) at 12 months, and 736 25 (P ¼ .04) at 2 years. In the
EVAR groups, eGFR deviated from 76 6 28
(suprarenal ﬁxation) and 75 6 23 (infrarenal) to 75 6 29
(P ¼ .7) and 77 6 26 (P ¼ .2) at 6 months, 71 6 28
(P ¼ .002) and 746 24 (P ¼ .74) at 12 months, and 716
27 (P ¼ .001) and 74 6 24 (P ¼ .22) at 2 years.
On average, those undergoing OR lost a mean
5.39 mL/min/1.73 m2 (P ¼ .48) within the time of
1 year and 5.49 units (P ¼ .42) after 2 years. The
JOURNAL OF VASCULAR SURGERY
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(P ¼ .002) after 1 year and 6.57 units (P ¼ .001) after
2 years on average. Finally, the infrarenal ﬁxation patients
lost 0.53 mL/min/1.73 m2 (P ¼ .74) after 1 year and
2.24 units (P ¼ .22) after 2 years.
There was no correlation between proximal neck
length or diameter at baseline and drop of eGFR. The
Pearson correlation for neck length was .13 (P ¼ .06) at
1 year and .14 (P ¼ .06) at 2 years. The Pearson correlation
for neck diameter was .09 (P ¼ .16) at 1 year and .05
(P ¼ .47) at 2 years.
The Fig summarizes changes in eGFR during the 2-
year study period.
DISCUSSION
This study examined the effects of elective open AAA
repair in comparison with two modalities of elective
EVAR on renal function measured with eGFR. The main
ﬁnding was that they have a very different effect on
midterm renal function. OR and EVAR with suprarenal ﬁx-
ation were associated with signiﬁcant progressive reduction
of eGFR during 2 years. EVAR with infrarenal ﬁxation did
not follow the same decline pattern and showed an average
loss of 2.2 mL/min/1.73 m2, which lies within the range
of physiologic eGFR decline. This suggests that two of the
modalities for AAA repair may signiﬁcantly affect the future
course of the patient’s renal function. This factor needs to
be taken into consideration in selecting the type of
intervention.
A number of mechanisms can be implicated with re-
gard to the documented adverse effects on renal function.
Open AAA repair requires general anesthesia and pro-
longed operating time. Further, cross-clamping of the aorta
can directly lead to renal artery complications.24 Cross-
clamping and lower limb ischemia also lead to a release
of cytokines and ischemia-reperfusion injury.24 The
EVAR techniques share the limitations of administration
of contrast material intraprocedurally and in serial
computed tomography investigations and renal microem-
bolization during endovascular manipulations. However,
our current ﬁndings conﬁrm our previous observations
that suprarenal ﬁxation has a more adverse impact.11 It
has been hypothesized that the presence of bare stents or
barbs above the renal arteries could be associated with renal
artery occlusion, thrombosis, or dissection.25,26 However,
as no renal artery stenosis, dissection, or occlusion was
seen on any of the computed tomography studies, this
drop in renal function must be attributed to factors that
cannot be picked up by computed tomography.
We also documented very different patterns of eGFR
drop for the three modalities. In OR, eGFR dropped on
average 4.4 mL/min/1.73 m2 within 6 months and then
another 1.1 units for the rest of the 18 months, suggesting
an effect restricted to the ﬁrst months after the operation,
possibly because of the perioperative shock. In contrast,
among the suprarenal EVAR ﬁxation group, the average
drop of eGFR during the ﬁrst 6 months is <1 unit, fol-
lowed by a drop of almost 6 units until 2 years. This issigniﬁcantly different compared with infrarenal ﬁxation
EVAR. Neck anatomy, on top of the suprarenal ﬁxation
component, may play a role in this. Suprarenally ﬁxated
devices are chosen in patients with more hostile necks.
None of our EVAR patients had excessive calciﬁcation or
thrombus, but the indications for suprarenal ﬁxation
included neck length <14 mm and neck of a conical
conﬁguration. These parameters can lead to more micro-
embolization. We did not, however, pick up any microem-
boli during follow-up CTA in our cohort in either the
infrarenal or the suprarenal group. This may be because
the study is underpowered to pick up microemboli (which
are rare).
Other studies have tried to examine the effect of open
AAA repair vs EVAR on renal function. An unmatched
cohort study evaluated 113 EVAR patients in comparison
to 65 patients undergoing OR during 36 months.5 It
included only serum creatinine concentration as a measure
of renal function, showing increasing trends in all groups.
Another retrospective study reported renal outcomes in pa-
tients with established renal insufﬁciency (serum creatinine
concentration >1.5 mg/dL) undergoing OR (n ¼ 46;
mean follow-up, 20 months) or EVAR (n ¼ 52, of which
19 had suprarenal ﬁxation; mean follow-up, 16 months).
There was an insigniﬁcant trend for worsening renal func-
tion in EVAR.7 Gawenda and Brunkwall6 reported a pro-
spective, unmatched, single-center cohort of patients
undergoing OR (n ¼ 229) or EVAR (suprarenal,
n ¼ 84; infrarenal, n ¼ 60). There was no change in serum
creatinine concentration and creatinine clearance (CrCl)
calculated by the Cockcroft-Gault formula with OR and
a small, insigniﬁcant decrease in renal function with
EVAR (deriving exclusively from a 4.8 mL/min drop in su-
prarenal ﬁxation). However, follow-up was only 8 days,
and the two groups were not balanced at baseline. Another
study included 24 EVARs with suprarenal ﬁxation and 28
ORs originating from various sources, including a random-
ized trial (EVAR 1).27 There were no differences in CrCl
and cystatin C during 12 months; however, CrCl differed
by 7 mL/min at baseline, favoring EVAR. A retrospective
study using eGFR as a measure of renal function8 examined
120 ORs and 103 EVARs. Again, there were no differences
at 23 months. A similar study, which represented a post
hoc analysis of renal function of patients recruited to the
EVAR 1 and EVAR 2 trials, used the MDRD formula to
compare patients managed with open or endovascular
repair or no intervention.28 For EVAR trial 1 (open vs
EVAR), the mean rate of change in eGFR was 1.13
and 1.00 unit per year (P ¼ .208). Even though the
data came from a randomized controlled trial (EVAR 1),
the groups were unmatched and imbalanced. Also, the de-
vices used in the EVAR 1 trial are not used in contempo-
rary practice. The initial report of the OVER (Open vs
Endovascular Repair) trial,29 in which more contemporary
devices were used, reported only dialysis-related renal out-
comes; the incidence of renal failure requiring dialysis in
those undergoing EVAR within 1 year was 1.1% and did
not differ from that in those undergoing OR (P ¼ .73).
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(Dutch Randomized Endovascular Aneurysm Manage-
ment) trial,31 comparing the renal function of 94 patients
undergoing EVAR vs 95 undergoing OR by use of the
CKD-EPI during 5 years. Mean absolute changes from
preoperative eGFR to 5-year eGFR were 0.8 and 0.9
unit per year (P ¼ .480) for OR and EVAR, respectively.
However, suprarenal ﬁxation and infrarenal ﬁxation were
not analyzed separately, and the patients did not follow
uniform radiologic surveillance. Also, neck anatomy was
not taken into account. Finally, Nquyen et al32 analyzed
9877 patients undergoing EVAR and 3314 undergoing
OR, all of whom had moderate or severe renal dysfunction
preoperatively; in patients with an eGFR between 30 and
60 units, the risk of dialysis was 5.2 higher in the open
group. In those with an eGFR <30, outcomes were similar
in both EVAR and OR.
The present study has a number of methodologic
strengths. First, it followed a nested case-control design,
whereby patients from prospective cohort databases were
matched for various factors by blinded investigators; this
led to group similarity by virtually all major factors that
can affect renal function. Second, it distinguished between
suprarenal and infrarenal EVAR ﬁxation; this was incorpo-
rated following evidence from our group that these two
modalities of ﬁxation have diverse effects on renal func-
tion.11,33 Third, we included only patients who have com-
plete renal function data for 2 years, a criterion absent from
all previous studies. All these may have reduced the study
sample to 225 patients, but it resulted in minimizing con-
founding from several sources. Fourth, this study employed
a uniform protocol for renal protection in EVAR as well as
a uniform pattern of radiologic follow-up. This is the ﬁrst
study of this kind to follow a standardized radiologic
follow-up for the EVAR arms. In addition, we used the
most up-to-date index of renal function. It is well estab-
lished that serum creatinine concentration is an insensitive
index of mild and moderate degrees of renal impairment
because it depends on several factors, the most important
of which is muscle mass.12 Also, the equation of Cockcroft
and Gault13,14 for CrCl carries some inherent limitations of
creatinine metabolism and overestimates renal function; it
also requires computation of body surface area before com-
parison to normal values. The MDRD study equation14
provides an accurate estimate of GFR.34 The more recently
developed CKD-EPI equation15 is suggested to be even
more accurate than the MDRD equation in populations
with cardiovascular comorbidity, such as patients with
AAA.16,35,36 Also, we not only examined eGFR levels,
but we also performed analysis of changes in eGFR, which
offered a more detailed picture of variation of renal func-
tion. Finally, the current study is the ﬁrst in the literature
to take proximal neck data into account at baseline.
This study is limited by the fact that it still is an obser-
vational study and not a clinical trial randomizing patients
to the three modalities. However, randomization would be
virtually impossible because of ethical implications, as prox-
imal neck anatomy still dictates the type of device thatwill be used. Furthermore, although all patients had
a follow-up of at least 2 years, this study cannot assess
whether the observed changes in eGFR would continue
to evolve during longer periods. Also, because of the
design of the study, we do not have data for renal function
immediately after the repair, and patients undergoing OR
and EVAR did not have the exact same renoprotection pre-
operatively as there is no evidence that this type of hydra-
tion or N-acetylcysteine administration has any impact on
renal function after OR. Data for 14 of the patients
included in the two EVAR groups have already been pub-
lished for up to 1 year of follow-up.11 Finally, we do not
have data regarding the exact duration of cross-clamping
in the OR patients; however, none of the patients had su-
prarenal aortic cross-clamping. Overall, we believe that
owing to the design strengths described, this study still pro-
vides the best available evidence to date.
CONCLUSIONS
This study suggests for the ﬁrst time that both open
AAA repair and suprarenal ﬁxation in EVAR are associated
with signiﬁcant declines in renal function during 2 years
compared with infrarenal EVAR ﬁxation. Also, the patterns
of eGFR decline in open AAA repair and suprarenal
ﬁxation are not similar, suggesting different causal mecha-
nisms. These observations have important implications for
clinical practice as they suggest an important beneﬁt of
aortic endografts with infrarenal ﬁxation. Before a speciﬁc
suprarenal or infarenal ﬁxation device is offered to any
patient, the patient’s renal function at baseline should be
taken into account together with the anatomic data, and
the clinician could possibly consider a device with added
columnar support (uniform body design) or use of other
modalities to increase proximal ﬁxation, such as endovascu-
lar staples.37 Future studies with randomized design and
long-term follow-up are necessary to provide a deﬁnite
answer.
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